SCHEMBL426870

SCHEMBL426870

CN(Cc1cccc(Cl)c1)C(=O)n1nnc2ccccc21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 5/20 0.56
MGLL Q99685 4/20 0.56
GLA P06280 1/20 0.49
THRB P10828 1/20 0.49
RIPK1 Q13546 1/20 0.47
F12 P00748 2/20 0.47
KMT2A Q03164 2/20 0.45
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
MAPT P10636 1/20 0.45
HTT P42858 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
PTK2 Q05397 1/20 0.45
MGAM O43451 3/20 0.44
AMY1A P0DUB6 3/20 0.44
GAA P10253 3/20 0.44
SI P14410 3/20 0.44
MGAM2 Q2M2H8 3/20 0.44
LMNA P02545 1/20 0.44
HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL425437 0.86 GAA (0.52) FAAHMGLLF12KMT2AKDM4E
SCHEMBL426868 0.84 F12 (0.53) FAAHMGLLF12KMT2AMAPT
SCHEMBL425707 0.82 TRPV1 (0.58) FAAHMGLLF12KMT2AKDM4E
SCHEMBL425705 0.80 MGAM (0.56) FAAHMGLLRIPK1F12KMT2A
SCHEMBL426780 0.77 ASAH1 (0.54) FAAHMGLLF12KMT2AKDM4E
SCHEMBL12648581 0.76 ASAH1 (0.60) FAAHMGLLGLATHRBF12
SCHEMBL426846 0.75 ASAH1 (0.58) FAAHMGLLF12KMT2AKDM4E
SCHEMBL425007 0.74 KMT2A (0.61) F12KMT2AKDM4EALDH1A1MAPT
SCHEMBL19380442 0.73 ASAH1 (0.55) FAAHMGLLGLATHRBF12
SCHEMBL426874 0.73 ASAH1 (0.59) FAAHMGLLF12KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
WO-2010074588-A2 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2010-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 FAAH 1/4885MGLL 11/4885GLA 901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.